Status:
COMPLETED
Humoral and Cellular Immunity in First-cycle SARS-CoV-2 Vaccinated COVID-19 Patients
Lead Sponsor:
University Magna Graecia
Conditions:
SARS CoV 2 Infection
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
Infection by the recent Coronavirus (SARS-CoV-2) has generated at a pandemic level a new pathology, called COVID-19, characterized by "flu-like" symptoms up to severe acute respiratory failure. The pa...
Eligibility Criteria
Inclusion
- Patients with a complete first-cycle vaccination against SARS-CoV-2 performed 4 to 7 months before.
Exclusion
- Presence of malignancy under chemotherapy
- Patient with previous transplantation
- Patient receiving immuno-modulatory or immunosuppressive drugs
- Patient receiving corticosteroid therapy since more than 10 days
- Pregnancy
- Consent withdrawal
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 27 2022
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT05338736
Start Date
April 1 2022
End Date
May 27 2022
Last Update
July 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AOU Mater Domini
Catanzaro, Italy